[HTML][HTML] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - Elsevier
Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
[PDF][PDF] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung …, 2016 - cyberleninka.org
abstract Objective: The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - infona.pl
The phase III IUNO trial assessed the benefit of maintenance erlotinib versus erlotinib at
progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not …
progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had not …
[引用][C] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - elibrary.ru
[PDF][PDF] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum …
S Cicènas, SL Geater, P Petrov, Y Hotko… - Lung …, 2016 - scholar.archive.org
abstract Objective: The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
[引用][C] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - cir.nii.ac.jp
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell
lung cancer who have not progressed following platinum-based chemotherapy (IUNO study) …
lung cancer who have not progressed following platinum-based chemotherapy (IUNO study) …
[PDF][PDF] Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum …
S Cicènas, SL Geater, P Petrov, Y Hotko, G Hooper… - Lung Cancer, 2016 - core.ac.uk
abstract Objective: The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based …
S Cicènas, SL Geater, P Petrov, Y Hotko… - Lung …, 2016 - lungcancerjournal.info
Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …
Maintenance erlotinib versus erlotinib at disease progression inpatients with advanced non-small-cell lung cancer who have notprogressed following platinum-based …
S Cicènas, S Lucien, GP Petrov, G Hooper, F Xia… - 2016 - dspace.uzhnu.edu.ua
Objective: The phase III IUNO trial assessed the benefit of maintenance erlotinib versus
erlotinib atprogression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had …
erlotinib atprogression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had …
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based …
S Cicènas, SL Geater, P Petrov, Y Hotko… - Lung Cancer …, 2016 - europepmc.org
Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib versus
erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had …
erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) that had …